Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 374.86 |
| Low | 374.86 |
| Bid | -- |
| Offer | -- |
| Previous close | 374.86 |
| Average volume | -- |
|---|---|
| Shares outstanding | 1.54bn |
| Free float | 1.33bn |
| P/E (TTM) | 666.55 |
| Market cap | 333.82bn HKD |
| EPS (TTM) | 0.313 HKD |
Data delayed at least 20 minutes, as of Nov 03 2025.
More ▼
Press releases
- BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
- ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
- BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
- BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
- BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
- Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
- U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
More ▼
